These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in Non-Somatotroph Pituitary Tumours and the Effects of PPARα Agonists on MMQ Cells. Polidoro MA; Rotondi S; Morace R; Rostomyan L; Colapietro A; Arcella A; Ventura L; Angelucci A; Giangaspero F; Esposito V; Beckers A; Jaffrain-Rea ML Horm Metab Res; 2018 Aug; 50(8):640-647. PubMed ID: 30021235 [TBL] [Abstract][Full Text] [Related]
4. Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line. Fukuda T; Tanaka T; Hamaguchi Y; Kawanami T; Nomiyama T; Yanase T PLoS One; 2016; 11(10):e0164131. PubMed ID: 27706259 [TBL] [Abstract][Full Text] [Related]
5. Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. Dénes J; Kasuki L; Trivellin G; Colli LM; Takiya CM; Stiles CE; Barry S; de Castro M; Gadelha MR; Korbonits M PLoS One; 2015; 10(2):e0117107. PubMed ID: 25658813 [TBL] [Abstract][Full Text] [Related]
6. miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance. Bogner EM; Daly AF; Gulde S; Karhu A; Irmler M; Beckers J; Mohr H; Beckers A; Pellegata NS Int J Cancer; 2020 Dec; 147(12):3523-3538. PubMed ID: 32856736 [TBL] [Abstract][Full Text] [Related]
7. A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion. Cai F; Hong Y; Xu J; Wu Q; Reis C; Yan W; Wang W; Zhang J World Neurosurg; 2019 Mar; 123():e45-e59. PubMed ID: 30447469 [TBL] [Abstract][Full Text] [Related]
8. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Oriola J; Lucas T; Halperin I; Mora M; Perales MJ; Alvarez-Escolá C; Paz de MN; Díaz Soto G; Salinas I; Julián MT; Olaizola I; Bernabeu I; Marazuela M; Puig-Domingo M Eur J Endocrinol; 2013 Jan; 168(1):9-13. PubMed ID: 23038625 [TBL] [Abstract][Full Text] [Related]
9. Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants. Hernández-Ramírez LC; Trivellin G; Stratakis CA Horm Metab Res; 2017 Apr; 49(4):286-295. PubMed ID: 28427099 [TBL] [Abstract][Full Text] [Related]
10. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332 [TBL] [Abstract][Full Text] [Related]
11. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Kasuki L; Vieira Neto L; Wildemberg LE; Colli LM; de Castro M; Takiya CM; Gadelha MR Endocr Relat Cancer; 2012 Jun; 19(3):L25-9. PubMed ID: 22420004 [No Abstract] [Full Text] [Related]
12. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. Vargiolu M; Fusco D; Kurelac I; Dirnberger D; Baumeister R; Morra I; Melcarne A; Rimondini R; Romeo G; Bonora E J Clin Endocrinol Metab; 2009 Jul; 94(7):2571-8. PubMed ID: 19366855 [TBL] [Abstract][Full Text] [Related]
13. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. Leontiou CA; Gueorguiev M; van der Spuy J; Quinton R; Lolli F; Hassan S; Chahal HS; Igreja SC; Jordan S; Rowe J; Stolbrink M; Christian HC; Wray J; Bishop-Bailey D; Berney DM; Wass JA; Popovic V; Ribeiro-Oliveira A; Gadelha MR; Monson JP; Akker SA; Davis JR; Clayton RN; Yoshimoto K; Iwata T; Matsuno A; Eguchi K; Musat M; Flanagan D; Peters G; Bolger GB; Chapple JP; Frohman LA; Grossman AB; Korbonits M J Clin Endocrinol Metab; 2008 Jun; 93(6):2390-401. PubMed ID: 18381572 [TBL] [Abstract][Full Text] [Related]
14. Markers of proliferation and invasiveness in somatotropinomas. Baldys-Waligorska A; Wierzbicka I; Sokolowski G; Adamek D; Golkowski F Endokrynol Pol; 2018; 69(2):182-189. PubMed ID: 29334118 [TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor α (PPARα) contributes to control of melanogenesis in B16 F10 melanoma cells. Grabacka M; Wieczorek J; Michalczyk-Wetula D; Malinowski M; Wolan N; Wojcik K; Plonka PM Arch Dermatol Res; 2017 Apr; 309(3):141-157. PubMed ID: 28084540 [TBL] [Abstract][Full Text] [Related]
16. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Jaffrain-Rea ML; Angelini M; Gargano D; Tichomirowa MA; Daly AF; Vanbellinghen JF; D'Innocenzo E; Barlier A; Giangaspero F; Esposito V; Ventura L; Arcella A; Theodoropoulou M; Naves LA; Fajardo C; Zacharieva S; Rohmer V; Brue T; Gulino A; Cantore G; Alesse E; Beckers A Endocr Relat Cancer; 2009 Sep; 16(3):1029-43. PubMed ID: 19556287 [TBL] [Abstract][Full Text] [Related]
17. Activated AMP-protein kinase (pAMPK) is overexpressed in human somatotroph pituitary adenomas. Bizzi MF; Drummond JB; Pinheiro SVB; Paulino E; Araújo SA; Soares BS; Giannetti AV; Schweizer JROL; Barry S; Korbonits M; Ribeiro-Oliveira A Mol Cell Endocrinol; 2024 Oct; 592():112318. PubMed ID: 38908427 [TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. Chahal HS; Trivellin G; Leontiou CA; Alband N; Fowkes RC; Tahir A; Igreja SC; Chapple JP; Jordan S; Lupp A; Schulz S; Ansorge O; Karavitaki N; Carlsen E; Wass JA; Grossman AB; Korbonits M J Clin Endocrinol Metab; 2012 Aug; 97(8):E1411-20. PubMed ID: 22659247 [TBL] [Abstract][Full Text] [Related]
19. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. Occhi G; Losa M; Albiger N; Trivellin G; Regazzo D; Scanarini M; Monteserin-Garcia JL; Fröhlich B; Ferasin S; Terreni MR; Fassina A; Vitiello L; Stalla G; Mantero F; Scaroni C J Neuroendocrinol; 2011 Jul; 23(7):641-9. PubMed ID: 21554434 [TBL] [Abstract][Full Text] [Related]
20. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant. Joshi K; Daly AF; Beckers A; Zacharin M Horm Res Paediatr; 2018; 90(3):196-202. PubMed ID: 29953972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]